Celonis Research Unveils: 89% of Business Leaders say AI Without Process Intelligence Fails to Deliver Expected Results
Celonis, the global leader in Process Mining and Process Intelligence, today released survey findings that demonstrate widespread recognition that AI requires Process Intelligence to be effective and relevant for the business. With Celonis Process Intelligence, AI gains the context it needs to understand how a business runs and how to make it run better.
The 2025 Process Optimization Report shows that the vast majority of enterprise leaders (89%) say it’s crucial that AI has the context of how their business runs if it is going to deliver meaningful results and increase operational efficiency. The majority (58%) worry that shortcomings in their processes may hinder AI’s effectiveness. The responses from over 1,600 global leaders underscore the critical role Process Intelligence plays in ensuring AI provides actionable insights, suggests impactful recommendations, and takes effective actions.
Key survey findings: Process Intelligence as the foundational enabler of AI
Nearly all enterprises are deploying AI, with only 1% of the business leaders surveyed saying they’re not. AI expectations are high for the year ahead and leaders recognize that effective AI and processes are intrinsically linked.
- 89% of leaders believe AI must understand how their business processes run to deliver effective results.
- 81% of companies plan to use AI specifically to improve business processes in the next 12 months.
- 74% of respondents say their AI budgets are increasing.
- 64% of respondents believe AI will deliver significant ROI.
- 61% of businesses report that AI applications like GenAI chatbots and assistants are already being deployed to enhance operational efficiency.
- 58% of leaders worry that process inefficiencies could limit the value they achieve from AI initiatives.
“AI agents need to be process aware - just like a GPS needs a map,” said Alex Rinke, co-founder and co-CEO of Celonis. “The survey results clearly demonstrate that business leaders recognize that there’s no effective AI without Process Intelligence. Our platform, powered by the Process Intelligence Graph, provides enterprise AI the data and context it needs to be truly game-changing.”
How Celonis enables effective enterprise AI
Celonis platform feeds AI agents with unique multi-system and system-independent Process Intelligence allowing them to make accurate decisions, suggest impactful recommendations, and take appropriate actions.
At Celosphere 2024, Celonis announced AgentC—a suite of AI agent tools, integrations, and partnerships that enables the Celonis community to use prebuilt AI agents or develop AI agents in the leading AI agent platforms powered by Celonis Process Intelligence.
Celonis’ role in enterprise AI has been validated by analysts and enterprise customers alike. Gartner named Celonis a leader in its 2024 Magic Quadrant™ for Process Mining Platforms, citing its ability to provide businesses with system-agnostic process insights enriched with AI-driven capabilities. Celonis also ranks 13 on Forbes 2024 Cloud 100 list, which recognizes the world’s leading private cloud companies in the areas of AI, software, infrastructure, security, and more.
How effective enterprise AI boosts productivity and profitability
To learn more about the strategies business leaders are using to optimize their processes, download the full report from https://www.celonis.com/processreport/. Along with the data shared here, the report contains information on how leaders are boosting productivity with automation, what’s limiting their ability to fully understand their processes, and which methods they’re using to gain process visibility. Four department-specific reports are also available for Finance and Shared Services, Supply Chain, Process and Operations, and IT.
Survey methodology
To create the 2025 Process Optimization Report, Celonis worked with an independent B2B and technology research consultancy to conduct 1,620 interviews with business leaders during July and August 2024. Respondents came from organizations with revenue of $500m+ and were spread across Australia, Austria, France, Germany, Japan, South Korea, Spain, Switzerland, the UK, and the US. All the leaders work in either Finance and Shared Services, Supply Chain, IT and Digital, or Process Improvement and Operations departments.
About Celonis
Celonis makes processes work for people, companies, and the planet. The Celonis Process Intelligence Platform, powered by process mining and AI, combines process data and business context to create a living digital twin of the enterprise, connecting people to processes, teams to each other, and AI to the business. Thousands of companies worldwide, including half of the top 200 companies on the Forbes Global 2000, use Celonis to understand their business, optimize operations and drive significant value across the top, bottom, and green lines.
Celonis is headquartered in Munich, Germany, and New York City, USA, with more than 20 offices worldwide.
© 2025 Celonis SE. All rights reserved. Celonis and the Celonis “droplet” logo are trademarks or registered trademarks of Celonis SE in Germany and other jurisdictions. All other product and company names are trademarks or registered trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250205166450/en/
Contacts
Media Contact
press@celonis.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma Partners With MBC BioLabs to Strengthen Global Innovation in Drug Discovery19.12.2025 02:00:00 CET | Press Release
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President & CEO: Toshiaki Nagasato) today announced that it has entered into a partnership agreement with MBC BioLabs which is a private organization supporting the development of biotech startup companies in California’s San Francisco Bay Area. MBC BioLabs provides fully equipped research facilities and a supportive community that help biotech entrepreneurs accelerate from concept to company. By removing the burden of building and maintaining laboratory infrastructure, resident companies can focus early on research and development while efficiently advancing commercialization. Through this partnership, Meiji Seika Pharma will further advance its open-innovation initiatives and strengthen research and development in its priority therapeutic areas: infectious diseases, hematologic diseases, and immune-inflammatory diseases. By engaging with the entrepreneurs and startup community at MBC BioLabs, the company aims to discover inn
Enry's Island SpA Strengthens Its Leadership in Venture Capital with Explosive Growth and Redesigns the Future of VC Through Gaming19.12.2025 00:34:00 CET | Press Release
Enry’s Island SpA (WBAG:EIOS), the world’s first publicly listed venture builder, announces a new era of growth, innovation, and the democratization of Venture Capital (VC). The company has delivered exceptional results, consolidating its position as an industry leader through a strategic positioning in the rapidly expanding gaming market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218742236/en/ Record Growth and Performance Enry’s Island SpA has demonstrated an extraordinary growth trajectory and a strong financial and operational track record: Revenues: +250% year-over-year (YoY). Exit: $3.6M in exits realized via IPO. Portfolio: 1 IPO of a portfolio company completed in December 2024, with an additional 2 IPOs expected in 2026. The performance of the EIOS:VSE stock reflects this strength: Price per Share (PPS): +132% in the first half (H1) of 2025, stabilizing at a +116% YTD increase. Daily Trading Volume: peaks of
500 Global Expands Africa Presence; Selected to Advance Digital Morocco 2030 Strategy18.12.2025 21:37:00 CET | Press Release
500 Global, one of the world’s most active venture capital firms1, announced it has been selected to support the Ministry-led Startup VB initiative, a flagship program under the Digital Morocco 2030 strategy2. This announcement marks a significant milestone in 500 Global’s continued expansion across the African continent and its work collaborating with governments to strengthen national innovation ecosystems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218363323/en/ Announcement of 500 Global's continued expansion across Africa and support of Digital Morocco 2030 Launched by the Ministry of Digital Transition and Administrative Reform (Ministry) and deployed by TAMWILCOM, the Startup VB initiative is a flagship program under the Digital Morocco 2030 strategy. Startup VB aims to strengthen Morocco’s innovation and digital competitiveness by accelerating high-potential founders and providing the training and financing pa
Neural Concept Closes $100M Funding Round Led by Growth Equity at Goldman Sachs Alternatives to Scale AI-Native Engineering18.12.2025 17:00:00 CET | Press Release
Neural Concept, a global AI platform and leader in Engineering Intelligence powering next-generation product development, today announced it raised a $100 million Series C funding round led by Growth Equity at Goldman Sachs Alternatives, with existing investors Forestay Capital, Alven, HTGF, D.E. Shaw Ventures and Aster Capital. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218764112/en/ Image courtesy of Neural Concept (L-R clockwise from top) Jonathan Donier, CSO & Co-founder; Thomas von Tschammer, Managing Director US & Co-founder; Théophile Allard, CTO & Co-founder; Pierre Baqué CEO & Co-founder; Philippe Cuendet, COO Neural Concept is redefining engineering workflows with CAD-native enterprise AI that understands geometry, constraints and design intent. By helping its customers build and deploy physics-aware design copilots, the platform enables teams to explore millions of design options earlier and avoid costly la
Croma-Pharma Introduces New Medical Device for the Preparation of Autologous PRP | Fluid- PRF18.12.2025 16:57:00 CET | Press Release
Croma-Pharma, a global player in minimally invasive aesthetic medicine, proudly announces the launch of its new medical device that is used for the preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin (Fluid-PRF).1 This launch represents continued progress in Croma’s mission to provide healthcare professionals state-of-the-art tools for their practice. With its innovative design and optimized separation technology, Exprecell™ enables the efficient preparation of autologous blood concentrates, without the use of anticoagulants, resulting in the formation of Fluid-PRF, a biologically active concentrate that retains the regenerative properties of platelets and leukocytes, yet stays liquid for a defined period.1 What makes Exprecell™ special? MDR certification: Exprecell™ is MDR-certified, meeting stringent EU regulatory requirements to ensure the safe, controlled and standardized preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom